Akari Therapeutics Reports Substantial Q1 Loss, Going Concern Warning, and Critical Liquidity Issues

summarizeSummary

Akari Therapeutics reported a significantly increased net loss and substantial impairment charges in Q1 2026, alongside a critical going concern warning due to a cash runway extending only into June 2026.

check_boxKey Events · Financing and Capital Events · AKTX

• Going Concern Warning Issued

  The company's cash balance of $2.8 million as of March 31, 2026, is insufficient to fund operations for the next year, raising substantial doubt about its ability to continue as a going concern.

• Extremely Short Cash Runway

  Existing cash is projected to fund operations only into June 2026, necessitating immediate additional capital.

• Increased Net Loss

  Q1 2026 net loss significantly widened to $14.5 million, compared to $3.7 million in Q1 2025.

• Significant Impairment Charges

  The company recognized $12.1 million in non-cash impairment losses on goodwill and other intangible assets due to a sustained decline in ADS price and market capitalization.

auto_awesomeAnalysis · AKTX · Life Sciences

This quarterly report highlights severe financial distress for Akari Therapeutics. The explicit "going concern" warning, coupled with a cash runway of only a few weeks (into June 2026) and minimal recent financing, indicates an urgent need for capital. The substantial increase in net loss and significant non-cash impairment charges further underscore the company's deteriorating financial health. While the company regained Nasdaq compliance through a reverse ADS split, the underlying operational and liquidity challenges remain critical. Investors should be aware of the high risk of further dilution or other drastic measures to secure funding.